Published in J Exp Med on April 11, 2005
Inflammatory bowel disease. Annu Rev Immunol (2010) 7.10
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology (2007) 2.55
PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut (2006) 1.99
Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol (2008) 1.79
Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut (2006) 1.77
5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology (2006) 1.62
PPARgamma in human and mouse physiology. Biochim Biophys Acta (2007) 1.58
Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol (2017) 1.42
Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol (2008) 1.28
Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respir Viruses (2009) 1.26
Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity. J Exp Med (2006) 1.19
SAMP1/YitFc mouse strain: a spontaneous model of Crohn's disease-like ileitis. Inflamm Bowel Dis (2011) 1.17
Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology (2009) 1.15
Advances in the pathogenesis and treatment of IBD. Clin Immunol (2009) 1.10
Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care (2010) 1.07
β-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARγ pathway. Am J Pathol (2011) 1.05
Nitrated oleic acid up-regulates PPARgamma and attenuates experimental inflammatory bowel disease. Free Radic Biol Med (2009) 1.04
Green Tea Polyphenols and Sulfasalazine have Parallel Anti-Inflammatory Properties in Colitis Models. Front Immunol (2013) 0.99
PPARγ in Inflammatory Bowel Disease. PPAR Res (2012) 0.96
PPARs Mediate Lipid Signaling in Inflammation and Cancer. PPAR Res (2008) 0.96
Signal transducer and activator of transcription 5b promotes mucosal tolerance in pediatric Crohn's disease and murine colitis. Am J Pathol (2006) 0.94
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. PLoS One (2014) 0.92
Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol (2011) 0.92
Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol (2010) 0.92
Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int J Mol Sci (2013) 0.92
Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol (2011) 0.91
New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease. Inflamm Bowel Dis (2010) 0.89
Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med Biol Res (2014) 0.88
Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochem Pharmacol (2012) 0.88
Probiotics, nuclear receptor signaling, and anti-inflammatory pathways. Gastroenterol Res Pract (2011) 0.88
Emerging drugs for the treatment of ulcerative colitis. Expert Opin Emerg Drugs (2009) 0.87
Ulcerative colitis: immune function, tissue fibrosis and current therapeutic considerations. Langenbecks Arch Surg (2011) 0.87
Mechanism of regulation of Na-H exchanger in inflammatory bowel disease: role of TLR-4 signaling mechanism. Dig Dis Sci (2011) 0.87
Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage-mediated fungal clearance during Pneumocystis pneumonia. PLoS Pathog (2010) 0.87
N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis. FASEB J (2014) 0.87
Inhibitory effect of rosiglitazone on the acid-induced intracellular generation of hydrogen peroxide in cultured feline esophageal epithelial cells. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.86
Tumour necrosis factor alpha blockade induces an anti-inflammatory growth hormone signalling pathway in experimental colitis. Gut (2006) 0.86
Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol (2012) 0.86
PPARγ and the Innate Immune System Mediate the Resolution of Inflammation. PPAR Res (2015) 0.85
Preclinical studies of a specific PPARγ modulator in the control of skin inflammation. J Invest Dermatol (2013) 0.85
PPARgamma Inhibitors as Novel Tubulin-Targeting Agents. PPAR Res (2008) 0.83
Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease. Ther Adv Chronic Dis (2015) 0.83
Overexpression of PAK1 promotes cell survival in inflammatory bowel diseases and colitis-associated cancer. Inflamm Bowel Dis (2015) 0.83
A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. World J Gastroenterol (2008) 0.83
Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol (2008) 0.83
Pathway-based approaches to the treatment of inflammatory bowel disease. Transl Res (2015) 0.83
Peroxisome proliferator activated receptor gamma and oxidized docosahexaenoic acids as new class of ligand. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.82
BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling. Gut (2015) 0.82
Brain-Gut-Bone Marrow Axis: Implications for Hypertension and Related Therapeutics. Circ Res (2016) 0.82
Current understanding of the role of PPARγ in gastrointestinal cancers. PPAR Res (2009) 0.81
Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer. Gastroenterol Clin North Am (2010) 0.81
Five-aminosalicylic Acid: an update for the reappraisal of an old drug. Gastroenterol Res Pract (2015) 0.81
Effectiveness of a hydroxynaphthoquinone fraction from Arnebia euchroma in rats with experimental colitis. World J Gastroenterol (2013) 0.81
Colon OCTN2 gene expression is up-regulated by peroxisome proliferator-activated receptor gamma in humans and mice and contributes to local and systemic carnitine homeostasis. J Biol Chem (2010) 0.81
Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPARγ-dependent pathway. Oncotarget (2016) 0.80
Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids. PLoS One (2012) 0.80
Colorectal cancer chemoprevention by mesalazine and its derivatives. J Biomed Biotechnol (2012) 0.80
Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib. J Lipid Res (2013) 0.80
Significance of anti-inflammatory effects of PPARgamma agonists? Gut (2006) 0.80
Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease. World J Gastroenterol (2015) 0.79
The Impact of PPARγ Genetic Variants on IBD Susceptibility and IBD Disease Course. PPAR Res (2012) 0.78
Pioglitazone, PPARγ agonist, attenuates experimental autoimmune neuritis. Inflammation (2012) 0.78
Role of Peroxisome Proliferator-Activated Receptor γ in Ocular Diseases. J Ophthalmol (2015) 0.78
The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγ. Carcinogenesis (2013) 0.78
Peroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitis. Dis Markers (2014) 0.78
Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels. Adv Ther (2015) 0.78
Understanding the Mechanism of 5-ASA in Treating Colonic Inflammation. Gastroenterol Hepatol (N Y) (2008) 0.77
Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2loxP/loxP Villin-Cre mice. Gut (2014) 0.77
Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2. Am J Physiol Gastrointest Liver Physiol (2014) 0.77
An insilico approach to high altitude pulmonary edema - Molecular modeling of human beta2 adrenergic receptor and its interaction with Salmeterol & Nifedipine. J Mol Model (2008) 0.77
Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. Dig Dis Sci (2011) 0.77
Amelioration of experimental colitis after short-term therapy with glucocorticoid and its relationship to the induction of different regulatory markers. Immunology (2016) 0.77
Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal? World J Gastrointest Pharmacol Ther (2015) 0.77
Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study. Dig Dis Sci (2009) 0.77
Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.77
Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases. World J Gastroenterol (2016) 0.77
PAK1 modulates a PPARγ/NF-κB cascade in intestinal inflammation. Biochim Biophys Acta (2015) 0.76
Gastrointestinal Cytoprotection by PPARγ Ligands. PPAR Res (2010) 0.76
Mesalamine suppresses the expression of TC22, a novel tropomyosin isoform associated with colonic neoplasia. Mol Pharmacol (2009) 0.76
Role of autophagy in the pathogenesis of inflammatory bowel disease. World J Gastroenterol (2017) 0.75
Combination of metformin and 5-aminosalicylic acid cooperates to decrease proliferation and induce apoptosis in colorectal cancer cell lines. BMC Cancer (2016) 0.75
Is there a biological basis for treatment of fibrodysplasia ossificans progressiva with rosiglitazone? Potential benefits and undesired effects. PPAR Res (2010) 0.75
Effects of Mesalamine Treatment on Gut Barrier Integrity After Burn Injury. J Burn Care Res (2016) 0.75
Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis. Inflamm Bowel Dis (2016) 0.75
Induction of Colonic Regulatory T Cells by Mesalamine by Activating the Aryl Hydrocarbon Receptor. Cell Mol Gastroenterol Hepatol (2017) 0.75
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease. Clin Exp Gastroenterol (2009) 0.75
Azathioprine, Mercaptopurine, and 5-Aminosalicylic Acid Affect the Growth of IBD-Associated Campylobacter Species and Other Enteric Microbes. Front Microbiol (2017) 0.75
Intestinal PPARγ signalling is required for sympathetic nervous system activation in response to caloric restriction. Sci Rep (2016) 0.75
Mesalazine Has No Effect on Mucosal Immune Biomarkers in Patients with Diarrhea-Dominant Irritable Bowel Syndrome Referred to Shariati Hospital: A Randomized Double-Blind, Placebo-Controlled Trial. Middle East J Dig Dis (2017) 0.75
Peroxisome proliferator-activated receptor-γ is downregulated in ulcerative colitis and is involved in experimental colitis-associated neoplasia. Oncol Lett (2015) 0.75
New Research in Ulcerative Colitis: Optimizing 5-ASA Administration for Efficacy and Adherence. Gastroenterol Hepatol (N Y) (2010) 0.75
The Expression of the Short Isoform of Thymic Stromal Lymphopoietin in the Colon Is Regulated by the Nuclear Receptor Peroxisome Proliferator Activated Receptor-Gamma and Is Impaired during Ulcerative Colitis. Front Immunol (2017) 0.75
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
The nuclear receptor superfamily: the second decade. Cell (1995) 24.99
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell (1994) 17.58
Development and validation of a genetic algorithm for flexible docking. J Mol Biol (1997) 14.36
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature (1998) 13.58
Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature (1998) 8.33
An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet (1977) 7.89
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes (1998) 6.53
Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J Comput Aided Mol Des (2002) 5.65
The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem (1997) 4.55
Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology (1978) 4.14
Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med (1996) 4.09
Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology (1989) 3.24
Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell (2000) 3.01
A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest (1999) 2.91
Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology (2004) 2.65
Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature (1998) 2.65
Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology (2003) 2.59
The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol (2000) 2.17
Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J Biol Chem (1997) 2.10
A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell (2001) 2.02
Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut (2002) 1.94
Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A (2001) 1.93
A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology (2003) 1.91
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology (1996) 1.59
Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet (2002) 1.50
Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem (2001) 1.48
Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther (1990) 1.44
What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut (1998) 1.43
Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology (2001) 1.41
Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest (2003) 1.40
Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem (1999) 1.38
Differential gene regulation by PPARgamma agonist and constitutively active PPARgamma2. Mol Endocrinol (2002) 1.37
Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol (1999) 1.35
Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology (1999) 1.35
PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res (2002) 1.29
Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis (2003) 1.20
Nitration of PPARgamma inhibits ligand-dependent translocation into the nucleus in a macrophage-like cell line, RAW 264. FEBS Lett (2002) 1.19
A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes (1999) 1.18
Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut (2000) 1.17
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev (2003) 1.13
Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther (1993) 1.13
Phosphorylation of transcriptional coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein (PBP). Stimulation of transcriptional regulation by mitogen-activated protein kinase. J Biol Chem (2002) 1.12
Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs (1989) 1.03
Selective intranuclear redistribution of PPAR isoforms by RXR alpha. Mol Endocrinol (2002) 1.01
Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression. A new mechanism of action for high density lipoprotein. J Biol Chem (2002) 0.95
Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther (1999) 0.94
Structural determinants of the ligand-binding site of the human retinoic acid receptor alpha. Biochemistry (1995) 0.87
Aminosalicylic acid inhibits IkappaB kinase alpha phosphorylation of IkappaBalpha in mouse intestinal epithelial cells. J Biol Chem (1999) 0.87
Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos (1999) 0.86
5-aminosalicylic acid inhibits iNOS transcription in human intestinal epithelial cells. Int J Mol Med (1999) 0.84
Limited proteolysis for assaying ligand binding affinities of nuclear receptors. Recept Signal Transduct (1997) 0.82
Distinct modes of interaction of the retinoic acid receptor alpha with natural and synthetic retinoids. Mol Cell Endocrinol (1998) 0.79
Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions. Scand J Gastroenterol (1991) 0.78
Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell (2006) 19.16
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature (2004) 12.36
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature (2009) 10.59
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature (2006) 9.36
TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab (2009) 6.91
Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis (2004) 6.83
High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology (2004) 5.94
Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab (2008) 5.44
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 5.03
Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology (2011) 4.88
Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell (2007) 4.71
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest (2004) 4.65
Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature (2008) 4.60
Autophagy is required to maintain muscle mass. Cell Metab (2009) 4.46
Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov (2008) 4.43
Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab (2008) 4.36
SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell (2002) 4.31
Mitonuclear protein imbalance as a conserved longevity mechanism. Nature (2013) 4.18
Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science (2011) 4.16
Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β. Nature (2012) 4.15
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc (2004) 4.12
PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol (2009) 4.09
Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A (2003) 4.03
Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med (2014) 4.00
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
A guide to analysis of mouse energy metabolism. Nat Methods (2011) 3.82
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Transcriptional regulation of metabolism. Physiol Rev (2006) 3.68
The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J Biol Chem (2005) 3.51
The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling. Cell (2013) 3.50
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev (2006) 3.48
Epithelial Bmpr1a regulates differentiation and proliferation in postnatal hair follicles and is essential for tooth development. Development (2004) 3.46
Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab (2010) 3.46
The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev (2009) 3.23
Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. Cell Metab (2006) 3.22
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab (2012) 3.18
Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) (2009) 3.15
Endocrine functions of bile acids. EMBO J (2006) 3.03
From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res (2006) 3.01
Nuclear receptors and the control of metabolism. Annu Rev Physiol (2002) 3.00
Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis. Am J Clin Nutr (2011) 2.98
Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes. Science (2010) 2.93
Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer (2004) 2.93
Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut (2011) 2.87
NCoR1 is a conserved physiological modulator of muscle mass and oxidative function. Cell (2011) 2.75
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74
E2Fs regulate adipocyte differentiation. Dev Cell (2002) 2.71
Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann Med (2007) 2.64
The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev Cell (2002) 2.61
Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc Natl Acad Sci U S A (2006) 2.60
Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med (2012) 2.59
Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology (2003) 2.59
Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol (2002) 2.58
Sequential roles of Brg, the ATPase subunit of BAF chromatin remodeling complexes, in thymocyte development. Immunity (2003) 2.56
Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology (2005) 2.52
Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology (2008) 2.52
Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell (2002) 2.50
Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. Genes Dev (2004) 2.49
Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc Natl Acad Sci U S A (2004) 2.46
CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest (2007) 2.44
Apoptotic extinction of germ cells in testes of Cyp26b1 knockout mice. Endocrinology (2007) 2.40
Transcriptional coregulators in the control of energy homeostasis. Trends Cell Biol (2007) 2.40
Sirtuin functions in health and disease. Mol Endocrinol (2007) 2.38
Synergy between LRH-1 and beta-catenin induces G1 cyclin-mediated cell proliferation. Mol Cell (2004) 2.31
The G0/G1 switch gene 2 is a novel PPAR target gene. Biochem J (2005) 2.29
PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab (2006) 2.26
Adipocyte NCoR knockout decreases PPARγ phosphorylation and enhances PPARγ activity and insulin sensitivity. Cell (2011) 2.26
Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol (2003) 2.26
LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends Cell Biol (2004) 2.24
The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J Biol Chem (2004) 2.23
Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell (2011) 2.22
TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab (2011) 2.17
Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med (2006) 2.16
Genome-wide RNA polymerase II profiles and RNA accumulation reveal kinetics of transcription and associated epigenetic changes during diurnal cycles. PLoS Biol (2012) 2.12
mTOR complex 2 in adipose tissue negatively controls whole-body growth. Proc Natl Acad Sci U S A (2009) 2.05
Histone methyl transferases and demethylases; can they link metabolism and transcription? Cell Metab (2010) 2.04
Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev (2004) 2.04
PPARbeta/delta regulates paneth cell differentiation via controlling the hedgehog signaling pathway. Gastroenterology (2006) 2.01
The pollutant diethylhexyl phthalate regulates hepatic energy metabolism via species-specific PPARalpha-dependent mechanisms. Environ Health Perspect (2010) 1.98
The BAF complex interacts with Pax6 in adult neural progenitors to establish a neurogenic cross-regulatory transcriptional network. Cell Stem Cell (2013) 1.96